ArticleThe Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation2021
Comparison of combined heart‒liver vs heart-only transplantation in pediatric and young adult Fontan recipients.
Article in The Journal of heart and lung transplantation : the official publication of the International Society for Heart Transplantation, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it, 52 citations in OpenAlex.
- Mortality Outcomes of Combined Heart and Liver Transplantation and Isolated Heart Transplantation Following Fontan Procedures: A Systematic Review and Meta-Analysis.Pediatric transplantation · 2025Pooled it
- Effect of liver abnormalities on mortality in Fontan patients: a systematic review and meta-analysis.BMC cardiovascular disorders · 2024Pooled it
- Long-Term Care in Fontan Circulation: Surveillance and Management of Fontan-Associated Liver Disease and Protein-Losing Enteropathy.Current cardiology reports · 2026Review
- Heart and combined heart-liver transplantation in Asian patients with Fontan circulatory failure: a single-center experience.Journal of cardiothoracic surgery · 2026Article
- Prognostic biomarkers in Fontan associated liver disease.Translational pediatrics · 2026Review
- Article
- Outcomes and complications of combined heart-liver transplantation in patients with failing Fontan physiology: A systematic review.World journal of transplantation · 2025Article
- Article
- Single ventricle care: challenges, successes and the future in a single center program.Translational pediatrics · 2025Review
- Fontan-Associated Liver Disease.Seminars in liver disease · 2025Review
- Multi-Organ Transplantation in Adult Congenital Heart Disease: Navigating the Unique Challenges of a Distinct Patient Population.Methodist DeBakey cardiovascular journal · 2025Review
- Pediatric Combined Heart-liver Transplantation: A Single-center Long-term Experience.Transplantation direct · 2024Article
- The majority of pediatric Fontan patients have excellent post-transplant survival.The Journal of thoracic and cardiovascular surgery · 2024Article
- Contemporary Management of the Failing Fontan.Journal of clinical medicine · 2024Review
- Rejection in the setting of combined Heart and Liver Transplantation.International journal of cardiology. Congenital heart disease · 2024Article
- Review of pediatric combined heart-liver transplantation: A roadmap to success.Pediatric transplantation · 2023Review
- Novel Therapeutic Strategies in Heart Failure in Adult Congenital Heart Disease: of Medicines and Devices.Current heart failure reports · 2023Review
- Narrative review of single ventricle: where are we after 40 years?Translational pediatrics · 2023Review
- Heart transplantation after Fontan operation.JTCVS techniques · 2022Article
- Management of circulatory failure after Fontan surgery.Frontiers in pediatrics · 2022Review
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
12 authors at 4 institutions in 2 countries.
Funding
Abstract
backgroundIndications for a heart‒liver transplantation (HLT) for Fontan recipients are not well defined. We compared listing characteristics, post-operative complications, and post-transplant outcomes of Fontan recipients who underwent HLT with those of patients who underwent heart-only transplantation (HT). We hypothesized that patients who underwent HLT have increased post-operative complications but superior survival outcomes compared with patients who underwent HT.
methodsWe performed a retrospective review of Fontan recipients who underwent HLT or HT at a single institution. Characteristics at the time of listing, including the extent of liver disease determined by laboratory, imaging, and biopsy data, were compared. Post-operative complications were assessed, and the Kaplan‒Meier survival method was used to compare post-transplant survival. Univariate regression analyses were performed to identify the risk factors for increased mortality and morbidity among patients who underwent HT.
resultsA total of 47 patients (9 for HLT, 38 for HT) were included. Patients who underwent HLT were older, were more likely to be on dual inotrope therapy, and had evidence of worse liver disease. Whereas ischemic time was longer for the group who underwent HLT, post-operative complications were similar. Over a median post-transplant follow-up of 17 (interquartile range: 5-52) months, overall mortality for the cohort was 17%; only 1 patient who underwent HLT died (11%) vs 7 patients who underwent HT (18%) (p = 0.64). Among patients who underwent HT, cirrhosis on pre-transplant imaging was associated with worse outcomes.
conclusionsDespite greater inotrope need and more severe liver disease at the time of listing, Fontan recipients undergoing HLT have post-transplant outcomes comparable with those of patients undergoing HT. HLT may offer a survival benefit for Fontan recipients with liver disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.